(MT Newswires) -- Novo Nordisk (NVO) Chief Executive Officer Lars Fruergaard Jorgensen discusses the possibility of its Ozempic drug's inclusion on the Biden administration's list of prescription drugs that will be subject to price negotiations with Medicare, US demand for its obesity medicine Wegovy, and acquisition strategy on Bloomberg Television.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
927.3 DKK | +1.13% | -0.16% | +32.83% |
31/05 | Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment | MT |
30/05 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.83% | 60TCr | |
+40.73% | 74TCr | |
-6.30% | 35TCr | |
+15.15% | 32TCr | |
+4.05% | 28TCr | |
+15.00% | 24TCr | |
+9.78% | 21TCr | |
-5.52% | 21TCr | |
+6.17% | 16TCr | |
-0.45% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo CEO on Ozempic, Wegovy Demand, Acquisition Strategy